Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | ESR1 | P03372 | 5/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.68 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | TNKS | O95271 | 1/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.58 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.58 |
| ▸ | MIF | P14174 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117813 | 0.90 | ALDH1A1 (0.64) | NPC1MAOBMAPTMEN1KMT2A | |
| SCHEMBL8934513 | 0.88 | ESR1 (0.88) | NPC1ESR1ESR2ERAP1MAOB | |
| SCHEMBL3366067 | 0.88 | ESR1 (0.88) | NPC1ESR1ESR2ERAP1MAOB | |
| SCHEMBL31675834 | 0.88 | ESR1 (0.82) | NPC1ESR1ESR2ERAP1MAOB | |
| SCHEMBL5082203 | 0.88 | ESR1 (0.82) | NPC1ESR1ESR2ERAP1MAOB | |
| SCHEMBL7117556 | 0.87 | ALDH1A1 (0.67) | NPC1MAOBMAPTMEN1KMT2A | |
| SCHEMBL8934624 | 0.86 | MAOB (0.60) | NPC1ESR1ESR2ERAP1MAOB | |
| SCHEMBL13183978 | 0.85 | ESR1 (0.80) | NPC1ESR1ESR2ATM | |
| SCHEMBL5427914 | 0.85 | NPC1 (1.00) | NPC1ESR1ESR2ERAP1MAOB | |
| SCHEMBL7463411 | 0.84 | MAOB (0.72) | NPC1MAOBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| US-6555523-B1 | Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus | CASCADE ESTATES LTD. (MU) | 2003-04-29 | — | — | US | disclosed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | NPC1 362/4885ESR1 258/4885ESR2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.